Novel Repositioning Therapy for Drug-Resistant Glioblastoma: <i>In</i> <i>vivo</i> Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide

Takeyoshi Eda(Niigata University), Manabu Natsumeda(Niigata University)
Preprints.org
December 23, 2021
10.20944/preprints202112.0396.v1
Cited by 1

Related Papers

The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma
|Cancer Letters|2017|68
Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high‐MYC medulloblastoma
|Neuropathology|2019|11
SGLT2 inhibition suppresses glioblastoma cell proliferation via AMPK activation and mTOR-dependent reduction of protein synthesis under glucose starvation
|Research Square|2026|0